- Home
- PHVS vs CIM Comparison
PHVS vs CIM Comparison
Compare PHVS & CIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHVS
- CIM
- Stock Information
- Founded
- PHVS 2015
- CIM 2007
- Country
- PHVS Switzerland
- CIM United States
- Employees
- PHVS N/A
- CIM N/A
- Industry
- PHVS Biotechnology: Pharmaceutical Preparations
- CIM Real Estate Investment Trusts
- Sector
- PHVS Health Care
- CIM Real Estate
- Exchange
- PHVS Nasdaq
- CIM Nasdaq
- Market Cap
- PHVS 980.9M
- CIM 1.1B
- IPO Year
- PHVS 2021
- CIM 2007
- Fundamental
- Price
- PHVS $20.06
- CIM $13.42
- Analyst Decision
- PHVS Buy
- CIM Buy
- Analyst Count
- PHVS 6
- CIM 3
- Target Price
- PHVS $37.17
- CIM $15.50
- AVG Volume (30 Days)
- PHVS 216.0K
- CIM 495.7K
- Earning Date
- PHVS 08-13-2025
- CIM 08-06-2025
- Dividend Yield
- PHVS N/A
- CIM 11.07%
- EPS Growth
- PHVS N/A
- CIM N/A
- EPS
- PHVS N/A
- CIM 1.28
- Revenue
- PHVS N/A
- CIM $312,281,000.00
- Revenue This Year
- PHVS N/A
- CIM $18.51
- Revenue Next Year
- PHVS N/A
- CIM $3.88
- P/E Ratio
- PHVS N/A
- CIM $10.41
- Revenue Growth
- PHVS N/A
- CIM 1.91
- 52 Week Low
- PHVS $11.51
- CIM $9.85
- 52 Week High
- PHVS $26.33
- CIM $16.89
- Technical
- Relative Strength Index (RSI)
- PHVS 48.84
- CIM 40.75
- Support Level
- PHVS $20.06
- CIM $12.78
- Resistance Level
- PHVS $22.30
- CIM $13.52
- Average True Range (ATR)
- PHVS 1.13
- CIM 0.26
- MACD
- PHVS -0.23
- CIM -0.07
- Stochastic Oscillator
- PHVS 22.84
- CIM 39.66
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
About CIM Chimera Investment Corporation
Chimera Investment Corporation is a real estate investment trust engaged in investing in a portfolio of mortgage assets on a leveraged basis. These investments include a variety of government-sponsored agency residential mortgage-backed securities, or RMBS, non-agency RMBS, agency commercial mortgage-backed securities, residential mortgage loans, and other real estate-related securities. Agency mortgage-backed securities represent the share of this portfolio, while subprime residential mortgage loans and non-agency RMBS also make up substantial shares.